In-vitro and in-vivo evaluation of the anticancer activity of diruthenium-2, a new trithiolato arene ruthenium complex [(eta(6)-p-MeC6H4Pri)(2)Ru-2(mu-S-p-C6H4OH)(3)]Cl

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216275%3A25310%2F16%3A39901609" target="_blank" >RIV/00216275:25310/16:39901609 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11150/16:10327591

Result on the web

<a href="http://journals.lww.com/anti-cancerdrugs/Citation/2016/08000/In_vitro_and_in_vivo_evaluation_of_the_anticancer.6.aspx" target="_blank" >http://journals.lww.com/anti-cancerdrugs/Citation/2016/08000/In_vitro_and_in_vivo_evaluation_of_the_anticancer.6.aspx</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/CAD.0000000000000374" target="_blank" >10.1097/CAD.0000000000000374</a>

Result language

angličtina

Original language name

In-vitro and in-vivo evaluation of the anticancer activity of diruthenium-2, a new trithiolato arene ruthenium complex [(eta(6)-p-MeC6H4Pri)(2)Ru-2(mu-S-p-C6H4OH)(3)]Cl

Original language description

In the present study, we investigated the anticancer action of the trithiolato arene ruthenium complex, [(?6-p-MeC6H4Pri)2Ru2(?-S-p-C6H4OH)3]Cl, named diruthenium-2, both in vitro and in vivo. The mechanism of antiproliferative, cytotoxic, and DNA-damaging activity, and the effect on expressions of cell cycle regulatory proteins were investigated using a WST-1-based proliferation assay, lactate dehydrogenase leakage assay, comet assay, flow cytometry, and western blot analysis. In-vivo anticancer activity was evaluated using Ehrlich tumor-bearing NMRI mice. Diruthenium-2 inhibited the growth of all cancer cell lines used, the most sensitive being gastric (AGS), breast cancer (BT-549, MCF-7, MDA-MB-231), and leukemic (HL- 60, MOLT-4) cells. In MCF-7 cells, it caused a G1/S cell cycle arrest, along with an increase in the expression of protein p21 and cyclin B1. We also observed increased levels of MRN complex proteins, which, together with the results from the comet assay, indicate the formation of DNA double-strand breaks. In tumor-bearing mice, diruthenium-2 at doses of 3 and 5 mg/kg inhibits the growth of solid Ehrlich tumor, although weaker than cisplatin. However, it did not prolong the post-therapeutic survival. Our results suggest the in-vitro potential of diruthenium-2 should be further evaluated in studies using other in-vivo models. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

CE - Biochemistry

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Anti-Cancer Drugs

ISSN

0959-4973

e-ISSN

—

Volume of the periodical

27

Issue of the periodical within the volume

7

Country of publishing house

US - UNITED STATES

Number of pages

8

Pages from-to

643-650

UT code for WoS article

000379037900006

EID of the result in the Scopus database

—